University of Minnesota

National Jewish Center for Immunology and Respiratory Medicine

New England Medical Center Hospitals. Inc.

Niche Biopharmaceuticals LLC

Hennepin Life Sciences, LLC

Patrick M Schlievert

Douglas Ohlendorf

Donald Y Leung

Marnie L Peterson

Cody Meissner

Dayton T Reardan

Paul Brennan

Manuela Roggiani

Jennifer Stoehr Stoehr

David Fulton

David T Mitchell

Brian L Kotzin

Pamela Gahr

Pamala J Gahr

The present invention provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate or a derivative thereof, and are administered topically, for example, to treat viral, fungal or bacterial infections.

Compositions for topical treatment of microbial infections

The disclosure relates generally novel sulfur containing glycerol mono-ester derivatives and methods useful for treating gram positive, gram negative, fungal and envelope viral infections in a patient.

Antimicrobial and antiviral sulfur containing glycerol monoester derivatives

The invention features methods of inhibiting the growth of, or killing, fungal and certain bacterial microorganisms with one or more of a family of glycerol-based compounds.

Compositions and methods for controlling infections

This disclosure features compositions that include two or more staphylococcal toxoids and are useful for inducing protective immune responses against staphylococcal diseases.

[object Object]

Cationic peptides and use of such peptides to inhibit bacterial exotoxin production without substantially inhibiting bacterial growth are described.

Cationic peptides and use of such peptides for inhibiting exotoxin production

This invention is directed to mutant SPE-A toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-A toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-A toxin. The mutant SPE-A toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-A toxin.

Mutants of Streptococcal toxin A and methods of use

Mutants of streptococcal toxin A and methods of use

This invention is directed to mutant SPE-C toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-C toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-C toxin. The mutant SPE-C toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-C toxin.

Mutants of Streptococcal toxin C and methods of use

Mutants of streptococcal toxin C and methods of use

Growing community of inventors

Iowa City, IA, United States of America

Patrick M Schlievert